Guidelines for avoiding risks resulting from discontinuation of nucleoside/nucleotide analogs in patients with chronic hepatitis B.
about
Update on Hepatitis B Virus Infection: Focus on TreatmentAdd-on Pegylated Interferon Alpha-2a Therapy in Chronic Hepatitis B Japanese Patients Treated with Entecavir.Mutations of pre-core and basal core promoter before and after hepatitis B e antigen seroconversionReimbursement policies in the Asia-Pacific for chronic hepatitis B.ZEB2 inhibits HBV transcription and replication by targeting its core promoter.New therapeutic perspectives in HBV: when to stop NAs.Telbivudine therapy for chronic hepatitis B: A journey to identify super-responders and to optimize treatment using the roadmap model.Monotherapy for hepatitis B infection: a review of treatment options.Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue/peg-interferon sequential therapy.Baseline HBsAg and HBcrAg titres allow peginterferon-based 'precision medicine' in HBeAg-negative chronic hepatitis B patients.Hepatitis B core-related antigen kinetics in chronic hepatitis B virus genotype D-infected patients treated with nucleos(t)ide analogues or pegylated-interferon-α.Factors associated with the effect of interferon-α sequential therapy in order to discontinue nucleoside/nucleotide analog treatment in patients with chronic hepatitis B.Hepatitis B core-related antigen: a strong indicator for cessation of nucleos(t)ide analog therapy in patients with chronic hepatitis B.Unmet Needs in Clinical and Basic Hepatitis B Virus Research.Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients?48-Week Outcome after Cessation of Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patient and the Associated Factors with Relapse.
P2860
Q26781990-F4C4268B-053C-489B-8C13-79F53483FE6BQ33604145-ACD02161-C46D-4331-AC1A-1D20717E1518Q34932600-000EB59F-F0C1-4A19-AE68-ACE6EBC792EAQ35580986-CE48A2ED-DE4C-45A8-AFA0-C5902B6D0EAFQ37085933-42BB6594-06F8-41E5-8065-633656C22546Q38174265-750249B7-DAF2-4E84-8286-4EE9E7129610Q38559455-D278A03D-1AB9-4DAE-878F-B630D4D415CAQ38594605-61A3841D-0F28-4E90-981F-89E22050425CQ40151821-58478F64-7B47-4B8D-BDE5-1CAD4F903DAFQ40499021-ECF642DF-4C6D-48B8-A7A6-B7FEC10102ACQ40557516-CC40E9EF-34AB-45C5-8A38-D60E92C41838Q42174830-29B2CA6C-4E14-46FE-8B23-CDA02BAB0518Q43975290-DBFC2D29-EEA7-45B7-ACD0-3101B62E0CB9Q45324577-75A8B8C8-5DC4-4097-95DE-3EF6D2462B02Q54217690-9AFB9441-F1D8-4086-A8BF-8566174FB71DQ55396049-F331E88C-3A57-4E22-A022-14973CCEFE76
P2860
Guidelines for avoiding risks resulting from discontinuation of nucleoside/nucleotide analogs in patients with chronic hepatitis B.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Guidelines for avoiding risks ...... ents with chronic hepatitis B.
@en
type
label
Guidelines for avoiding risks ...... ents with chronic hepatitis B.
@en
prefLabel
Guidelines for avoiding risks ...... ents with chronic hepatitis B.
@en
P2860
P356
P1433
P1476
Guidelines for avoiding risks ...... ents with chronic hepatitis B.
@en
P2093
Akihiro Matsumoto
Eiji Tanaka
P2860
P356
10.1111/HEPR.12108
P577
2013-05-07T00:00:00Z